INTRODUCTION: Seralutinib is an inhaled tyrosine kinase inhibitor targeting platelet-derived growth factor receptor (PDGFR)
- Sitbon, O.
- Sahay, S.
- Escribano Subías, P.
- Zolty, R. L.
- Kingrey, J. F.
- Ryan, J. J.
- Sobol, I.
- Sood, N.
- Benza, R. L.
- Channick, R. N.
- Chin, K. M.
- Frantz, R. P.
- Ghofrani, H. A.
- Hemnes, A. R.
- McLaughlin, V. V.
- Vachiéry, J. L.
- Zamanian, R. T.
- Ter Veer, A.
- Roscigno, R. F.
- Mottola, D.
- Parsley, E.
- Aranda, R.
- Zisman, L. S.
- Howard, L. S.
Keywords
- Efficacy
- Inhaled tyrosine kinase inhibitor
- Long-term
- PDGFR inhibitor
- Pulmonary arterial hypertension
- Pulmonary vascular resistance
- Safety
- Seralutinib
